Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES M FARBER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1144218215
CMS profile
324458
Location
MORRISTOWN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$110,128.15

326 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Seagen Inc. $40,117.12 43
Incyte Corporation $21,522.19 22
Kite Pharma, Inc. $16,124.10 17
AstraZeneca Pharmaceuticals LP $7,008.94 17
GENZYME CORPORATION $5,447.08 11
ADC Therapeutics America, Inc. $3,285.00 2
MorphoSys, US Inc. $3,119.91 4
Novartis Pharmaceuticals Corporation $2,490.32 22
Genentech USA, Inc. $2,378.54 9
PFIZER INC. $2,154.34 12
Janssen Biotech, Inc. $1,668.27 9
BeiGene USA, Inc. $1,350.00 1
E.R. Squibb & Sons, L.L.C. $687.85 18
Celgene Corporation $316.51 28
Regeneron Healthcare Solutions, Inc. $269.35 3
Astellas Pharma US Inc $252.13 7
Amgen Inc. $221.97 11
GlaxoSmithKline, LLC. $196.01 6
EISAI INC. $179.85 12
Pharmacosmos Therapeutics Inc. $157.91 4
Merck Sharp & Dohme LLC $155.72 11
Takeda Pharmaceuticals U.S.A., Inc. $155.38 5
Karyopharm Therapeutics Inc. $148.88 5
Daiichi Sankyo Inc. $86.63 6
Gilead Sciences, Inc. $60.08 4
Rigel Pharmaceuticals, Inc. $51.26 3
Exelixis Inc. $45.35 3
Ipsen Biopharmaceuticals, Inc $44.36 3
Janssen Pharmaceuticals, Inc $42.22 3
SERVIER PHARMACEUTICALS LLC $39.85 3
Bayer HealthCare Pharmaceuticals Inc. $39.69 2
Lilly USA, LLC $34.43 2
Genmab U.S., Inc. $33.72 2
ABBVIE INC. $30.62 2
Taiho Oncology, Inc. $29.50 2
Emmaus Medical, Inc. $22.09 1
Foundation Medicine, Inc. $19.85 1
MACROGENICS, INC. $18.12 1
PharmaEssentia USA Corporation $14.77 1
PUMA BIOTECHNOLOGY, INC. $14.71 1
Boehringer Ingelheim Pharmaceuticals, Inc. $14.69 1
Pharmacyclics LLC, an AbbVie Company $14.56 1
Duchesnay USA Incorporated $14.04 1
TerSera Therapeutics LLC $13.78 1
CTI BioPharma Corp. $13.18 1
Helsinn Therapeutics (U.S.), Inc. $12.71 1
ARRAY BIOPHARMA INC $10.57 1

Page 2 of 7; records 51–100 of 326 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES M FARBER

NPI 1144218215 · CMS profile ID 324458

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

MORRISTOWN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 7; records 51–100 of 326 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144218215?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES M FARBER, NPI 1144218215, CMS profile ID 324458. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 326 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144218215?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CHARLES M FARBER, NPI 1144218215, CMS profile ID 324458. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 326 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144218215?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CHARLES M FARBER, NPI 1144218215, CMS profile ID 324458, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 7; records 51–100 of 326 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1144218215?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

326 matching records · $110,128.15 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 326 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 326.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $23.1911/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938764143 CMS
MorphoSys, US Inc. $3,075.0011/03/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962539451 CMS
Novartis Pharmaceuticals Corporation $12.8111/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893625011 CMS
Celgene Corporation $1.8111/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586911 CMS
Daiichi Sankyo Inc. $14.1711/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930878599 CMS
Celgene Corporation $2.4411/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586877 CMS
Celgene Corporation $14.5711/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586889 CMS
Pharmacyclics LLC, an AbbVie Company $14.5611/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890339917 CMS
Novartis Pharmaceuticals Corporation $14.9010/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893625009 CMS
ARRAY BIOPHARMA INC $10.5710/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949477535 CMS
Amgen Inc. $14.3610/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939915883 CMS
Daiichi Sankyo Inc. $14.3710/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930869125 CMS
PFIZER INC. $14.9510/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949558449 CMS
Pharmacosmos Therapeutics Inc. $112.1610/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959140325 CMS
Daiichi Sankyo Inc. $17.0010/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930869533 CMS
MorphoSys, US Inc. $16.1510/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962539479 CMS
PharmaEssentia USA Corporation $14.7710/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941280445 CMS
Karyopharm Therapeutics Inc. $11.5010/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946514073 CMS
Lilly USA, LLC $16.2910/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917939925 CMS
Janssen Biotech, Inc. $15.2710/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886189290 CMS
EISAI INC. $15.8510/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 910872541 CMS
E.R. Squibb & Sons, L.L.C. $15.0010/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586881 CMS
Exelixis Inc. $16.2510/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932468115 CMS
E.R. Squibb & Sons, L.L.C. $14.5210/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586873 CMS
Kite Pharma, Inc. $4,980.0010/14/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920069561 CMS
Kite Pharma, Inc. $11.2410/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920069641 CMS
Kite Pharma, Inc. $38.7510/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920069643 CMS
Kite Pharma, Inc. $130.0010/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920069645 CMS
Merck Sharp & Dohme LLC $13.9610/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944241063 CMS
Seagen Inc. $3,520.0010/13/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904090469 CMS
Seagen Inc. $856.2710/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904090471 CMS
Seagen Inc. $124.7410/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904090635 CMS
Seagen Inc. $3,520.0010/12/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904090473 CMS
Seagen Inc. $16.4710/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904090629 CMS
Seagen Inc. $119.8110/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904090637 CMS
Takeda Pharmaceuticals U.S.A., Inc. $11.5410/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956058307 CMS
Novartis Pharmaceuticals Corporation $12.1910/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893625003 CMS
Novartis Pharmaceuticals Corporation $15.7210/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893625007 CMS
Amgen Inc. $13.2410/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939915875 CMS
PFIZER INC. $14.1910/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949401731 CMS
Celgene Corporation $9.3810/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586879 CMS
Kite Pharma, Inc. $18.5010/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920066249 CMS
MACROGENICS, INC. $18.1210/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927057675 CMS
Genentech USA, Inc. $15.6910/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950750285 CMS
PFIZER INC. $14.9509/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949332249 CMS
Celgene Corporation $14.4209/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586865 CMS
Celgene Corporation $2.8909/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586885 CMS
Celgene Corporation $0.8409/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586887 CMS
Novartis Pharmaceuticals Corporation $16.6209/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893625001 CMS
AstraZeneca Pharmaceuticals LP $15.5309/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920239179 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $81,307.80 220
PY2020 $66,312.52 90
PY2021 $72,517.88 148
PY2022 $110,128.15 326
PY2023 $143,595.80 382
PY2024 $80,401.87 296
PY2025 $54,593.44 200

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $593,856.82 59
PY2024 Principal investigator $944,635.04 88
PY2023 Recipient $5,752.90 4
PY2023 Principal investigator $673,470.87 76
PY2022 Recipient $26,660.00 1
PY2022 Principal investigator $714,802.51 97
PY2021 Recipient $940.00 1
PY2021 Principal investigator $455,066.94 96
PY2020 Principal investigator $498,104.54 71
PY2019 Recipient $1,424.43 6
PY2019 Principal investigator $157,413.02 16

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

59 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $122.18 12/31/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1232932481
Principal investigator 1 SANOFI US SERVICES INC. $2,683.14 12/08/2025 Non-covered Recipient Entity
Partners In Innovation Education Research Consortium LLC
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226133068
Principal investigator 1 BeOne Medicines Ltd. $7,179.00 11/17/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190333037
Principal investigator 1 BeOne Medicines Ltd. $162.03 11/10/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335226
Principal investigator 1 BeOne Medicines Ltd. $52,400.00 11/06/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190337185
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,160.00 11/06/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1236000536
Principal investigator 1 SANOFI US SERVICES INC. $1,788.76 10/06/2025 Non-covered Recipient Entity
Partners In Innovation Education Research Consortium LLC
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226133060
Principal investigator 1 SANOFI US SERVICES INC. $894.38 09/15/2025 Non-covered Recipient Entity
Partners In Innovation Education Research Consortium LLC
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226133052
Principal investigator 1 BeOne Medicines Ltd. $1,477.00 09/10/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190343204
Principal investigator 1 BeOne Medicines Ltd. $1,000.00 09/08/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190333025
Principal investigator 1 BeOne Medicines USA, Inc. $1,909.00 08/18/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190339465
Principal investigator 1 BeOne Medicines Ltd. $52,400.00 08/13/2025 Non-covered Recipient Entity
MORRISTOWN MEDICAL CENTER
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190330105
Principal investigator 1 BeOne Medicines Ltd. $400.00 08/11/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190333028
Principal investigator 1 SANOFI US SERVICES INC. $894.38 08/11/2025 Non-covered Recipient Entity
Partners In Innovation Education Research Consortium LLC
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226133046
Principal investigator 1 BeOne Medicines Ltd. $104,800.00 08/04/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190330221
Principal investigator 1 ABBVIE INC. $1,500.00 07/16/2025 Non-covered Recipient Entity
PARTNERS IN INNOVATION
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202498430
Principal investigator 1 BeOne Medicines Ltd. $400.00 07/14/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190333033
Principal investigator 1 SANOFI US SERVICES INC. $2,683.14 07/07/2025 Non-covered Recipient Entity
Partners In Innovation Education Research Consortium LLC
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226133034
Principal investigator 1 BeOne Medicines Ltd. $1,477.00 06/20/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190338799
Principal investigator 1 BeOne Medicines Ltd. $650.00 06/16/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190326592
Principal investigator 1 Eli Lilly and Company $5,416.00 06/11/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) No dispute reported 06/30/2026 1187874231
Principal investigator 1 SANOFI US SERVICES INC. $894.38 06/09/2025 Non-covered Recipient Entity
Partners In Innovation Education Research Consortium LLC
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226133031
Principal investigator 1 BeOne Medicines Ltd. $2,229.00 06/02/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190326312
Principal investigator 1 BeOne Medicines Ltd. $52,400.00 05/28/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190330283
Principal investigator 1 BeiGene, Ltd. $52,400.00 05/20/2025 Non-covered Recipient Entity
MORRISTOWN MEDICAL CENTER
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190321822
Principal investigator 1 ABBVIE INC. $3,000.00 05/06/2025 Non-covered Recipient Entity
PARTNERS IN INNOVATION
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202481343
Principal investigator 1 SANOFI US SERVICES INC. $3,782.14 05/05/2025 Non-covered Recipient Entity
Partners In Innovation Education Research Consortium LLC
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226133029
Principal investigator 1 BeiGene, Ltd. $2,415.00 04/21/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320762
Principal investigator 1 BeiGene, Ltd. $2,100.00 04/21/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320776
Principal investigator 1 BeiGene, Ltd. $203.00 04/21/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320780
Principal investigator 1 BeiGene, Ltd. $1,486.00 04/21/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320854
Principal investigator 1 BeiGene, Ltd. $900.00 04/21/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190321232
Principal investigator 1 BeiGene, Ltd. $1,000.00 04/21/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190321234
Principal investigator 1 BeiGene, Ltd. $2,142.00 04/21/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190322942
Principal investigator 1 BeiGene, Ltd. $2,622.00 04/21/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190322980
Principal investigator 1 SANOFI US SERVICES INC. $4,890.00 04/14/2025 Non-covered Recipient Entity
Partners In Innovation Education Research Consortium LLC
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226133025
Principal investigator 1 SANOFI US SERVICES INC. $7,016.38 04/02/2025 Non-covered Recipient Entity
Partners In Innovation Education Research Consortium LLC
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226133017
Principal investigator 1 SANOFI US SERVICES INC. $3,994.00 03/17/2025 Non-covered Recipient Entity
Partners In Innovation Education Research Consortium LLC
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226133021
Principal investigator 1 BeiGene, Ltd. $1,477.00 03/14/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324344
Principal investigator 1 BeiGene, Ltd. $125.00 03/10/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190322782
Principal investigator 1 BeiGene, Ltd. $1,300.00 03/10/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190322784
Principal investigator 1 ABBVIE INC. $5,038.00 03/07/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202416507
Principal investigator 1 BeiGene, Ltd. $52,400.00 03/05/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190323696
Principal investigator 1 BeiGene, Ltd. $52,400.00 02/25/2025 Non-covered Recipient Entity
MORRISTOWN MEDICAL CENTER
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190323478
Principal investigator 1 ABBVIE INC. $2,214.00 02/20/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202416491
Principal investigator 1 ABBVIE INC. $12,700.00 02/20/2025 Non-covered Recipient Entity
PARTNERS IN INNOVATION
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202453152
Principal investigator 1 SANOFI US SERVICES INC. $3,621.00 02/18/2025 Non-covered Recipient Entity
Partners In Innovation Education Research Consortium LLC
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226133008
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,000.00 02/12/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy ADRIATIC No dispute reported 06/30/2026 1185551469
Principal investigator 1 SANOFI US SERVICES INC. $13,042.00 01/24/2025 Non-covered Recipient Entity
Partners In Innovation Education Research Consortium LLC
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226133010
Principal investigator 1 BeiGene, Ltd. $1,246.00 01/21/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190322780
Principal investigator 1 SANOFI US SERVICES INC. $10,249.91 01/21/2025 Non-covered Recipient Entity
Partners In Innovation Education Research Consortium LLC
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226133005
Principal investigator 1 BeiGene, Ltd. $2,415.00 01/15/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320020
Principal investigator 1 BeiGene, Ltd. $44.00 01/15/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324254
Principal investigator 1 BeiGene, Ltd. $2,622.00 01/15/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324262
Principal investigator 1 BeiGene, Ltd. $2,142.00 01/15/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324326
Principal investigator 1 BeiGene, Ltd. $1,477.00 01/15/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324376
Principal investigator 1 BeiGene, Ltd. $540.00 01/06/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324208
Principal investigator 1 BeiGene, Ltd. $83.00 01/06/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324610
Principal investigator 1 Celgene Corporation $37,851.00 01/03/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1222305324